CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 165 enrolled
Drug / intervention
AGN-210669 ophthalmic solution, 0.1% +3 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01001195
NCT01001195Phase 2Completed
CompareCT.gov

Safety and Efficacy of Three Formulations of AGN-210669 Ophthalmic Solution Compared With Bimatoprost Ophthalmic Solution

Allergan·interventional·Posted Oct 26, 2009·Updated Oct 18, 2013

In Brief

A Phase 2 clinical trial evaluating AGN-210669 ophthalmic solution, 0.1%, AGN-210669 ophthalmic solution, 0.075%, and 2 other interventions for Glaucoma, Open-Angle and Ocular Hypertension. Completed, enrolled 165 participants across 1 site.

Detailed Summary

This study will evaluate the safety, efficacy and dose-response of AGN-210669. This study will also compare AGN-210669 with bimatoprost ophthalmic solution (LUMIGAN®).

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsGlaucoma, Open-Angle, Ocular Hypertension
CountriesUnited States
Collaborators--

Timeline

Phase 2CompletedFinished
20102011201220132014201520162017201820192020202120222023202420252026
First PostedOct 26, 2009
Enrollment StartNov 1, 2009
Primary CompletionApr 1, 2010
TodayJul 2, 2026
Enrollment to primary: 5 monthsPosted 16.7 years ago

Interventions

AGN-210669 ophthalmic solution, 0.1%drug

One drop of AGN-210669 ophthalmic solution, 0.1% in both eyes each evening from Day 1 through the evening prior to Day 29. Selected sites: One additional drop in both eyes on Day 29.

AGN-210669 ophthalmic solution, 0.075%drug

One drop of AGN-210669 ophthalmic solution, 0.075% in both eyes each evening from Day 1 through the evening prior to Day 29. Selected sites: One additional drop in both eyes on Day 29.

AGN-210669 ophthalmic solution, 0.05%drug

One drop of AGN-210669 ophthalmic solution, 0.05% in both eyes each evening from Day 1 through the evening prior to Day 29. Selected sites: One additional drop in both eyes on Day 29.

bimatoprost ophthalmic solution 0.03%drug

One drop of bimatoprost ophthalmic solution 0.03% in both eyes each evening from Day 1 through the evening prior to Day 29. Selected sites: One additional drop in both eyes on Day 29.